Modelling the economic and clinical burden of non‐alcoholic steatohepatitis in East Asia: Data from Hong Kong
- 14 June 2020
- journal article
- research article
- Published by Wiley in Hepatology Research
- Vol. 50 (9), 1024-1031
- https://doi.org/10.1111/hepr.13535
Abstract
Aim Non‐alcoholic steatohepatitis (NASH) is the progressive form of non‐alcoholic fatty liver disease (NAFLD) and prevalence is rising in Asia due to increasing rates of urbanization, sedentary lifestyles, and poor nutrition. Methods We built a Markov model with 20‐year horizon to estimate the burden of NASH in Hong Kong. Cohort size was determined by population size, prevalence of NAFLD, and incidence of NASH in 2017. Health states include hepatic steatosis, fibrosis stages 0–3, compensated and decompensated cirrhosis, hepatocellular carcinoma, post‐liver transplant, and liver‐related, cardiovascular, and background mortality. Transition probabilities were estimated from published reports and we converted 2017 Gazette price from the Hospital Authority of Hong Kong to US dollars. We discounted costs by 3% annually. Health utilities were assumed to be the same as in the USA. Results Non‐alcoholic steatohepatitis will cost $1.32 billion and 124 liver transplants over 20 years, with average cost per person‐year of $257. Sensitivity analyses show our model is robust in predicting costs for the prevalent population but likely overestimates costs for the incident population. Conclusions Non‐alcoholic steatohepatitis will contribute to a significant clinical and economic burden in Hong Kong over the next two decades. Due to the limited number of donors and small number of liver transplants undertaken annually, patients with advanced liver disease due to NASH in Hong Kong are more likely to die from NASH than their counterparts in North America and Europe. Thus, rising prevalence of metabolic syndrome in elderly adults in Hong Kong make NASH an important consideration for clinicians and policy makers.Keywords
This publication has 17 references indexed in Scilit:
- Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysisThe Lancet Gastroenterology & Hepatology, 2019
- Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United StatesHepatology, 2019
- Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)Medicine, 2018
- New trends on obesity and NAFLD in AsiaJournal of Hepatology, 2017
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver DiseasesHepatology, 2017
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomesHepatology, 2015
- Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance SpectroscopyThe American Journal of Gastroenterology, 2015
- High prevalence of non‐alcoholic fatty liver disease in the Chinese – results from the Hong Kong liver health censusLiver International, 2014
- Nonalcoholic Fatty Liver Disease in Lean Individuals in the United StatesMedicine, 2012
- Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastographyGut, 2011